Compound Disalbaspidin PB and application of compound Disalbaspidin PB in antibiosis

A compound and anti-bacterial technology, applied in the field of medicine, can solve the problem of few active ingredients, achieve clear structure, good application prospects, and promote effective application

Active Publication Date: 2020-06-05
GUANGDONG PHARMA UNIV +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are very few studies on its specific active ingredients, so there is an urgent need to study and develop antibacterial drugs from natural sources under the guidance of traditional Chinese medicine theory and modern pharmacology and pharmacodynamics.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound Disalbaspidin PB and application of compound Disalbaspidin PB in antibiosis
  • Compound Disalbaspidin PB and application of compound Disalbaspidin PB in antibiosis
  • Compound Disalbaspidin PB and application of compound Disalbaspidin PB in antibiosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Extraction and Identification of Disalbaspidin PB

[0051] 1. Extraction method

[0052] The method for extracting compound Disalbaspidin PB from D. figure 1 As shown, it specifically includes the following steps:

[0053] S1. Extraction of extract: 10kg of dry powder of Trichophyllum chrysalis is refluxed and extracted twice at room temperature with 50% ethanol by volume fraction of 10 times, the time is 2 hours respectively, the pH is adjusted to 2.4 with hydrochloric acid, and the medicine soaked in ethanol The liquid is concentrated and extracted to obtain 1.2kg of extract;

[0054] S2. After dissolving the precipitated extract sample obtained in S1, mix the sample with silica gel, perform preliminary separation on the silica gel column, and use different proportions of petroleum ether: acetone (100:1, 70:1, 50:1, 30:1, 10:1,1:1), to obtain the corresponding components A (96g), B (320g), C (60g), D (305g), E (160g), F (100g);

[0055] S3. Take componen...

Embodiment 2

[0071] Example 2 The inhibitory effect of Disalbaspidin PB on fungi

[0072] 1. Experimental method

[0073] Gently scrape the colonies on the surface of the SDA medium with an inoculation loop, grind the mycelium with a sterile grinder, suspend the dermatophytes in sterile saline, adjust the turbidity to 0.5 McFarland turbidity, and count the spores with a hemocytometer number and number of short hyphae. Make the bacterial concentration 1×10 3 CFU / mL to 3×10 3 CFU / mL. That is, the 0.5 McFarland turbidity bacteria solution was diluted 1000 times with RPMI-1640 liquid medium, and counted by the hemocytometer to obtain the inoculum solution. Use RPMI-1640 liquid medium to dilute the stock solution (20μg / mL) of Trichofernium monomer in the first column of 96-well plate, use the culture medium to carry out horizontal 2-fold dilution to the 10th column, add 100μL RPMI- 1640 liquid medium, add 200 μL RPMI-1640 liquid medium to column 12. Then add 100 μL of the inoculum solutio...

Embodiment 3

[0081] Example 3 The inhibitory effect of Disalbaspidin PB on bacteria

[0082] 1. Experimental method

[0083] Test method: The microdilution method is used, which is often used to determine the antibacterial activity of sensitive drugs or new drugs against human pathogenic bacteria. The operation method is simple and can be used for a large number of antibacterial tests. Using nutrient broth medium, the activated clinical pathogenic strains were inoculated into the medium to prepare a bacterial liquid, and the drug to be tested was dissolved in DMSO to prepare 64mg / mL. Dilute the drug to be tested line by line in a 96-well plate by two-fold decreasing dilution method; then add the diluted bacterial solution, and set aside two wells as a control, one well only adds medium, and the other well only Add bacterial solution, shake and mix evenly after dilution, then place the 96-well plate in a 35°C constant temperature incubator and incubate for 18-24 hours. The minimum inhibito...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, and particularly discloses a dryopteris fragrans compound Disalbaspidin PB and an application of the dryopteris fragrans compound Disalbaspidin PB in the antibacterial aspect. According to the invention, the phloroglucinol compound Disalbaspidin PB is separated and prepared from Dryopteris fragrans(L)Schott. The research results show thatthe compound has a good antibacterial effect on dermatophyte and bacteria, is low in side effect and not prone to drug resistance, provides a new choice and approach for development of antifungal andbacterial infection drugs, and has a good application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to a compound DisalbaspidinPB and its application in antibacterial. Background technique [0002] Bacteria play a vital role in the environment, but they also pose a great threat to human life and health. The extensive use of clinical antibiotics has exerted a huge selection pressure on bacteria, which inevitably leads to the emergence of drug resistance. The alarming increase in bacterial resistance to existing clinically commonly used drugs is a serious problem facing antimicrobial drug selection, and bacterial resistance to existing antimicrobial agents is also one of the leading causes of morbidity and mortality worldwide one. [0003] In addition, the incidence of clinical fungal infection is also on the rise, and fungal infection has attracted people's attention. According to the standards prevailing in the international medical community, fungal infection...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07C49/723C07C45/78A61K31/122A61P31/04A61P31/10A61P17/00
CPCC07C49/723C07C45/78A61P31/04A61P31/10A61P17/00Y02A50/30
Inventor 沈志滨王帅帅
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap